

3-Months Report 2005





MediGene's Pipeline of Innovative Anti-Tumor Drugs

Products	Diseases	Clinical Phases		Clinical Phases		Commer- cialization	Market Potential¹) (million €)
		I					· · ·
Eligard [®]	Prostate Cancer						> 100 ²⁾
Polyphenon [®] E Ointment	Genital Tumors						> 100
	Actinic Keratosis ³⁾						> 200
EndoTAG-1	Pancreatic Cancer						> 200
	Prostate Cancer						> 200
Oncolytic HSV	Liver Metastases						> 200
	Brain Tumors (Glioblastoma)						> 300
Chance of Reaching the Market:		10 – 30 %	40 – 60 %	60 – 80	90 %		

products jointly developed or marketed with biotech or pharmaceuticals companies.

1) Annually; maximum sales potential. MediGene will receive royalties on sales of 2) Marketing partnership with Astellas (formerly known as Yamanouchi) ³) Precursor of a specific type of skin cancer


Contents

Key Figures **3** Our Share **4** Interim MD&A Q1-2005 **5** Interim Financial Statement **13** Selected Details on the Notes **17**

Key Figures 3-Months Report 2005


		Q1- 2005	Q1- 2004	Change
Total revenues	T€	3,824	3,910	-2 %
Cost of sales	T€	372	28	>200 %
R&D expenses	T€	3,298	3,795	-13 %
Net loss from continued				
operations (EBIT)	T€	-1,260	-1,311	4 %
Personnel expenses from continued				
operations	T€	2,398	2,092	15 %
Employees	Number	120	110	9 %
Cash flow from operating				
activities	T€	-3,596	599	>-200 %
Cash flow from investing				
activities	T€	-124	-53	-134 %
Cash flow from financing				
activities	T€	14	15,998	>-200 %
Cash and cash equivalents at end of				
period	T€	44,737	37,983	18 %
Net loss per share from continued				
operations	€	0.05	0.10	-50 %

Total Revenues




R&D Expenses

in T€




Cash flow from Operating Activities

in T€




Cash and Cash Equivalents

in T€



The MediGene Share Price

(January 3, 2005 € 8.70 indexed to 100)



Key Figures for the Share

		3M-2005	3M-2004
3 months high	€	11.66	8.19
3 months low	€	8.70	6.06
Price at beginning of the year	€	8.70	6.06
Average price since			
beginning of the year	€	10.62	6.76
Closing price	€	10.37	7.85
Number of shares (March 31)		18,535,514	13,474,032
Average number of shares		18,529,099	12,340,119
Average market capitalization	million €	196.78	83.42
Average daily trading volume	in shares	142,635	120,489

Interim MD&A 3M-2005

- o Total revenues of 3.8 million € (Q1-2004: 3.9 million €)
- o Net loss 0.9 million € (Q1-2004: 1.5 million €)
- o Average monthly net cash burn rate in Q1-2005 of 1.3 million € (Q1-2004: 0.2 million € cash inflow)
- o Cash position 44.7 million € (2004: 38.0 Mio. €)
- o First time adoption of International Financial Reporting Standards (IFRS)

PRELIMINARY NOTES

MediGene develops anti-cancer and anti-tumor drugs

MediGene's core competence lies in research into and development of novel approaches for the treatment of various cancer and tumor diseases. Thus MediGene focuses on indications of high medical need and great economic opportunities. Apart from the drug Eligard[®] which is already available on the market, R&D and technology contracts, payments received within cooperation agreements for the joint development and commercialization of products as well as product commercialization by MediGene represent potential sources of revenue.

Eligard[®] was launched on the German market in May 2004. In December 2004, MediGene obtained approval for Eligard[®] in 23 additional European countries (not including Great Britain) within the mutual recognition procedure. In the first quarter of 2005, MediGene received the first national approvals, enabling the company to prepare for commercialization in the respective countries. Eligard[®] is marketed by MediGene's partner Astellas Pharma Europe Ltd. (the former Yamanouchi Ltd.)

Concerning another drug candidate, Polyphenon[®] E Ointment, MediGene published positive results from two independent clinical phase III trials in the indication genital warts. Marketing authorization application shall be submitted to the American regulatory authorities in the third quarter 2005, and afterwards to the European authorities. In addition, MediGene is currently conducting a clinical phase II trial to examine the potential of this ointment in the indication actinic keratosis, a precursor of skin cancer. Publication of the results obtained in this trial is scheduled for the second quarter 2005.

Apart from that, the efficacy of oncolytic herpex simplex viruses (drug candidate NV1020) for the treatment of liver metastases from colorectal carcinoma is examined. A clinical phase I/II trial was initiated in September 2004. Completion of this trial is scheduled for 2006.

A clinical phase II trials in the indication pancreatic cancer is currently in preparation for the product candidate EndoTAG-1 which was acquired in August 2004. This trial is scheduled for initiation in the second half of 2005.

CONSOLIDATED INCOME STATEMENT

For the first time this quarterly report has been prepared pursuant to International Accounting Standards (IFRS). For detailed explanations of the quarterly statements, see Notes (p. 17), and the consolidated statements of 2003 and 2004. Except for the adjustments outlined, the transition to IFRS with respect to accounting and valuation methods does not lead to major deviations of the consolidated financial statements prepared according to US-GAAP.

Total Revenues

Total revenues of 3,824 T€ have remained almost unchanged compared to last year's reporting period (Q1-2004: 3,910 T€). These revenues were generated solely by the commercialization of the drug Eligard[®] which has been marketed in Germany by MediGene's partner Astellas Pharma Europe Ltd. since May 2004. In addition to milestone payments due upon further approvals in Europe, and an upfront payment partially recognized as revenue, proceeds from product sales and licenses have been posted.

Consolidated Income Statement (Abbreviated)					
	Q1-2005	Q1-2004	Change		
in T€	unaudited	unaudited			
Total revenues	3,824	3,910	-2 %		
Cost of sales	372	28	>200 %		
Gross profit	3,452	3,882	-11%		
General, administrative and selling					
expenses	1,414	1,398	1 %		
Research and development					
expenses	3,298	3,795	13 %		
EBIT	-1,260	-1,311	4 %		
Net loss from continued					
operations	-947	-1,222	23 %		
Result from discontinued					
operations	-1	-281	100 %		
Net loss	-948	-1,503	37 %		

Cost of Sales

Cost of sales for Eligard[®] amounted to 372 T€. Costs were allocated to the purchase of the drug and to royalties paid to QLT Inc.. Since Eligard[®] was not launched until May 2004, the cost accruing in last year's reporting period was significantly lower (Q1-2004: 28 T€). First quarter revenues primarily result from milestone payments and the partial recognition of an upfront payment for which no cost of sales incurred.

Gross Profit

Gross profit decreased by 11% to 3,452 T€ (Q1-2004: 3,882 T€). This decline is mainly due to an increase in cost of sales and a reduction in the portion of milestone payments in total revenues.

General, Administrative and Selling Expenses

Compared to last year's reporting period, general, administrative and selling expenses remained almost unchanged, i.e. 1,414 T€ (Q1-2004: 1,398 T€).

R&D Expenses

In the first quarter 2005, total R&D expenses were reduced by 13 % to 3,298 T€ (Q1-2004: 3,795 T€). This decrease is mainly due to the change in the Polyphenon[®] E Ointment development stage. This ointment was in two clinical phase III trials during the first quarter of last year.

Depreciation

Total depreciation remained almost unchanged, amounting to 356 T€ (Q1-2004: 361 T€). Since August 2004, depreciation also includes depreciation of the assets acquired from Munich Biotech AG. Depreciation of LARNAX GmbH is reported under discontinued operations.

Depreciation and Amortization of tangible and intangible assets will not be reported separately, but allocated instead to selling, general and administration expenses, and to research and development expenses.

Depreciation			
in T€	Q1-2005 unaudited	Q1-2004 unaudited	Change
fixed assets including intangibles	307	145	112 %
capital lease	49	38	29 %
Total from continued operations	356	183	95 %
Discontinued operations	0	178	-100 %
Total	356	361	-1 %

EBIT

Operating result before interest and tax improved by 4 % to -1,260 T€ in the first quarter 2005 (Q1-2004: -1,311 T€).

Financial Result

The financial result increased by 252 % to 313 T€. Apart from higher interest income resulting from a higher amount invested, foreign currency exchange gains mainly from the exchange of Atrix shares for QLT shares also contributed to this.

Financial Result			
	Q1-2005	Q1-2004	
in T€	unaudited	unaudited	Change
Interest income	226	99	128 %
Interest expenses	-38	-8	>200 %
Foreign currency exchange gains/losses	125	-2	>200 %
Total	313	89	>200 %

3-Months Loss

Compared to last year's reporting period, the net loss was reduced by 37 % to -948 T€ (Q1-2004: -1,503 T€). This improved result is mainly due to the reduction in R&D expenses and the improvement in the financial result.

Loss per Share

In the first three months of the financial year, the loss per share from continued operations was reduced by 50 % from -0.10 \in (weighted average number of shares 18,529,099) to -0.05 \in (weighted average number of shares: 12,340,119).

The diluted net loss as of reporting date corresponds to the actual loss, since the conversion of common stock equivalents would have an anti-dilutive effect.

SEGMENT REPORTING

During the reporting period, MediGene's business activities were focused on the development of anti-cancer and anti-tumor drugs. These activities are divided into the specialty pharma and biopharma segments, as well as an unallocated segment. The specialty pharma segment comprises the drug Eligard[®] and the product candidate Polyphenon[®] E Ointment. The biopharma segment includes MediGene's EndoTAG and the oncolytic herpes simplex viruses technology, as well as the product candidates EndoTAG-1, NV1020, and G207 emanating from these technologies.

Segment reporting by market	segments			
	Specialty	Bio-		
in T€	pharma	pharma	Unallocated	Tota
Q1-2005				
Total revenues	3,813	0	10	3,823
Cost of sales	372	0	0	372
Gross profit	3,441	0	10	3,45′
General, administrative and				
selling expenses	2	0	1,412	1,414
Research and development				
expenses	976	2.321	0	3,298
EBIT	2,463	-2,321	-1,402	-1,260
Employees	25	62	33	120
Investments*	0	93	17	11(
Q1-2004				
Total revenues	3,860	23	27	3,882
Cost of sales	28	0	0	28
Gross profit	3,832	23	27	3,882
General, administrative and				
selling expenses	31	0	1.367	1,398
Research and development				
expenses	1,857	1,938	0	3,79
EBIT	1,944	-1,915	-1,340	-1,311
Employees	21	54	35	11(
Investments*	0	43	10	53

* Investments also include finance lease investments

ASSETS POSITION

Cash Position 44.7 million €; Equity Ratio 89 %

Compared with the closing date December 31, 2004, the cash position decreased by 8 % to 44,737 T€. The equity ratio increased to 89 %, partially due to the continued repayment of a loan from Aventis.

Changes in assets and capital structure

in T€	March 31, 2005	December 31, 2004	Change
Assets			
Long-term investments	2,454	2,894	-15 %
Goodwill	9,226	9,226	0 %
Fixed assets	8,360	8,585	-3 %
Cash and cash equivalents	44,737	48,460	-8 %
Other current assets	3,497	3,729	-6 %
Total assets	68,274	72,894	-6 %
Liabilities and shareholders' equity			
Shareholders' equity	60,474	61,711	-2 %
Long-term liabilities	1,856	1,880	-1 %
Current liabilities	5,944	9,303	-36 %
Total liabilities	68,274	72,894	-6 %
Liquidity cover ratio	66 %	66 %	0 %
Equity ratio	89 %	85 %	4 %

Financial position

Cash flow from operating activities


In the first three months of 2005, cash flow from operating activities was -3,596 T€ (Q1-2004: cash inflow of 599 T€). The difference between net loss (948 T€) and cash flow mainly results from repayment of a loan from Aventis, and the cash-neutral recognition of deferred revenues affecting net income. This deferred income affects the still unrealized portion of the upfront payment of 4,000 T€ which MediGene had received in the first quarter of 2004 upon conclusion of the Eligard[®] marketing partnership with Astellas Pharma Europe Ltd. The pro-rata recognition of deferred revenues resulted from the approval for Eligard[®] received in additional European countries.

As of closing date March 31, 2005, cash and cash equivalents amounted to 44,737 T€. MediGene is using cash and cash equivalents available for the development of its drug candidates.

Monthly Net Cash Burn Rate

According to the consolidated cash flow statements, the net cash burn rate from operating activities for Q1-2005 (net cash used during the reporting period) amounts to $-3,813 \text{ T} \in (\text{Q1-2004}: 462 \text{ T} \in)$, and a monthly average rate of -1,271 T \in (Q1-2004: 154 T \in). Proceeds from capital increases, stock options and convertible bonds and proceeds from acquisitions are not considered.

Development of cash and cash equivalents Q1-2005



Human Resources

Due to the recruitment of new employees in the field of EndoTAG technology (biopharma segment), headcount at our headquarters in Martinsried has increased compared to last year's reporting period.

Number of employees as of closing date March 31, 2005, and December 31, 2004						
	Q1-2005	Q1-2004	Y-2004			
MediGene AG	112	94	108			
MediGene, Inc.	8	16	9			
Total from continued						
operations	120	110	117			
Discontinued						
operations	0	2	0			
Total	120	112	117			
Personnel expenses in T€	Q1-200	5 Q1-2004	Change			
	Q1-200	0 Q1-2004	onange			
Total from continued operations	2,39	8 2,092	15 %			
Discontinued						
operations	(0 39	-100 %			
Total	2,39	8 2,131	13 %			

Risk Report

Legal disputes

Following the market launch of Eligard[®], Takeda Chemical Industries, Takeda Pharma GmbH and Wako Pure Chemical Industries (Takeda/Wako) sued the partners MediGene AG and Yamanouchi Pharma GmbH (renamed Astellas Pharma Europe Ltd. after the merger with Fujisawa) in summer 2004 for alleged patent infringement before the Duesseldorf district court. In this suit they argue that the commercialization of MediGene's and Astella's drug Eligard[®] infringes specific claims of one of the plaintiffs' patents. Prior to that, MediGene had already filed an action for invalidity of the contested patent before the Federal Patent Tribunal in Germany, whereupon all claims potentially relevant for Eligard[®] were declared invalid on April 20, 2005. In addition, parallel patent infringement proceedings are ongoing in the USA. MediGene's supplier and licensor QLT USA, Inc., and the US marketing partner of QLT USA, Inc., Sanofi-Synthelabo Inc. have been sued for patent infringement by Takeda Abbott Pharmaceutical Product Inc., Takeda Chemical Industries, Ltd und Wako Pure Chemical Industries, Ltd.

Major Events Since End of Period under Review

No major changes to the state of business have occurred up to April 30, 2005.

Forecast

Forecast for the year has been confirmed: reduction of net loss - cash 38 million € at the end of 2005

In 2005, MediGene expects to raise revenues to approximately 20 million \in . At the same time MediGene is planning to further improve the result; the net loss for the year 2005 should be less than 10 million \in . The cash position at the end of the year is expected to be approximately 38 million \in .

Market launch of Eligard[®] planned in additional European countries

In December 2004, the mutual recognition procedure for approval of the one-month and three-months products of Eligard[®] was successfully completed in 23 European countries (not including Great Britain). The first national approvals have already been granted during the reporting period. Therefore MediGene expects the successive approval and market launch in other European countries.

Polyphenon[®] E Ointment – completion of the clinical phase II trial in actinic keratosis expected in the second quarter 2005

End of October 2004, MediGene reported the completion of patient recruitment for a clinical phase II trial of the Polyphenon[®] E Ointment for the treatment of the skin disease actinic keratosis (precursor of skin cancer). A total of over 60 patients was admitted to the trial which investigates efficacy and tolerability of Polyphenon[®] E Ointment in the indication actinic keratosis. The sales potential of Polyphenon[®] E Ointment in this indication is estimated at not less than 200 million € annually, provided that the multi-stage development phase and marketing authorization procedure are successful.

Polyphenon[®] E Ointment – submission of marketing authorization application to the US authorities and conclusion of a marketing partnership planned

MediGene is currently compiling marketing authorization application for the Polyphenon[®] E Ointment and schedules to submit it to the American regulatory authorities in the second half of the year 2005, and afterwards to the European authorities. Moreover, a marketing partnership for the Polyphenon[®] E Ointment should be concluded by the end of the year 2005.

Polyphenon[®] E Ointment is developed for the treatment of benign tumors of the genital tract, so-called genital warts. In March and December 2004, respectively, two clinical phase III trials with more than 500 patients each participating in the USA and in Europe were completed with positive results.

EndoTAG-1 - clinical development program resumed in phase II

At present, a clinical phase II trial of EndoTAG-1 in the indication pancreatic cancer is in preparation. The first trial is to be initiated in the second half of 2005. The market potential for this indication is expected to reach more than 200 million €.

Consolidated Balance Sheet of MediGene AG as of March 31, 2005, and December 31, 2004

in T€	March 31,	December 31,
III IE	2005	2004
	unaudited	unaudited
Assets		
A. Long-term assets		
 Property, plant & equipment 	1,458	1,565
II. Intangible assets	6,902	7,020
III. Goodwill	9,226	9,226
IV. Investments	2,321	2,761
V. Other assets	133	133
Total long-term assets	20,040	20,705
B. Current assets		
I. Inventories	432	0
II. Accounts receivable	57	115
III. Cash & cash equivalents	44,737	48,460
IV. Other current assets	3,008	3,614
Total current assets	48,234	52,189
	40,234	52,109
Total assets	68,274	72,894
Lightitian and charabelders' as with in TC		
Liabilities and shareholders' equity in T€		
A. Shareholders' equity	19 526	10 500
I. Share capital	18,536	18,523
Number of shares issued and outstanding:		
December 31, 2004: 18,522,684		
March 31, 2005: 18,535,514	057 000	050 000
II. Additional paid-in capital	257,032	256,882
III. Accumulated deficit	-214,612	-213,665
IV. Net income recognized directly in equity	-482	-29
Total shareholders' equity	60,474	61,711
B. Long-term liabilities		
 Long-term debt less current portion 	1,686	1,674
II: Other long-term liabilities	60	55
III. Capital lease obligation less current portion	74	115
IV. Pension accrual	36	36
Total long-term liabilities	1,856	1,880
C. Current liabilities		
I. Trade accounts payable	1,234	618
II. Other current liabilities	1,511	3,463
III. Current portion of capital lease obligation	235	269
IV. Accruals	2,297	2,953
V. Deferred income	667	2,000
Total short-term liabilities	5,944	9,303
	60.07	
Total liabilities and shareholders' equity	68,274	72,894

Consolidated Income Statements

of MediGene AG for the periods from January 1 to March 31, 2005, and 2004

	Q1-2005	Q1-2004
in T€	unaudited	unaudited
1. Product sales	3,762	3,857
2. Other operating income	62	53
3. Total revenues	3,824	3,910
4. Cost of sales	372	28
5. Gross profit	3,452	3,882
6. Selling expenses	229	299
General and administrative expenses	1,185	1,099
8. Research and development expenses	3,298	3,795
9. Operating loss	-1,260	-1,311
10. Interest income and expenditures	188	91
11. Foreign currency exchange gains/losses	125	-2
12. Loss before income tax	-947	-1,222
13. Tax	0	0
14. Net loss from continued operations	-947	-1,222
15. Result from discontinued operations	-1	-281
16. Net loss for the period	-948	-1,503
Per share data in €:		
Result from continued operations ("actual" and "fully diluted ")	-0.05	-0.10
Result including discontinued operations ("actual" and "fully diluted")	-0.05	-0.12
Weighted average number of shares outstanding	18,529,099	12,340,119

The number of shares used in calculating the diluted net loss per share is the same as used in calculated the basic net loss per share since conversion of common stock equivalents would have an anti-dilutive effect. The number of potentially dilutive shares related to options and convertible bonds that could dilute basic earnings per share in the future was 919,309 as of March 31, 2005, and 915,720 as of March 31, 2004.

IRFS Totals may vary due to rounding

	Shares	Share capital	Capital reserves	Accumu- lated losses	Net income directly recognized in equity	Total share- holders' equity
	No.	T€	T€	T€	T€	T€
Balance January 1, 2005 audited (US-GAAP)	18,522,684	18,523	256,411	-213,248	-1,003	61,683
IFRS adjustment			471	-1,416	975	30
Balance January 1, 2005 unaudited (IFRS)	18,522,684	18,523	256,882	-213,664	-28	61,713
Net loss for the period				-948		-948
Unrealized loss from QLT Inc. shares					-441	-441
Currency translation adjustments					-13	-13
Comprehensive income						-1,402
Capital increase						0
Exercised options/bonds	12,830	13	65			78
Expenses on new options/bonds			85			85
Balance March 31, 2005						
unaudited	18,535,514	18,536	257,032	-214,612	-482	60,474
Balance January 1, 2004						
audited (US-GAAP)	11,206,205	11,206	218,177	-199,942	-221	29,220
IFRS adjustment			110	-1,057	975	28
Balance January 1, 2004	40.000.005	44.000	040.007		754	00.040
unaudited (IFRS)	12,206,205	11,206	218,287		754	29,248
Net loss for the period Unrealized gain from				-1,504		-1,504
QLT Inc. shares					425	425
Currency translation					τ∠J	723
adjustments					1	1
Comprehensive income						-1,078
Capital increase	2,245,670	2,246	13,246			15,492
Capital increase expenses			-861			-861
Exercised options/bonds	22,157	22	46			68
Expenses on new	,					
options/bonds			95			95
Balance March 31, 2004 unaudited	13,474,032	13,474	230,813	-202,503	1,180	42,964

Consolidated Cash Flow Statements

of MediGene AG for the periods from January 1 to March 31, 2004, and 2005

	Q1-2005	Q1-2004
in T€	unaudited	unaudited
Cash flow from operating activitities		
Net loss for the period (before and after tax)	-948	-1,503
Adjustments to reconcile net loss with cash used in		
operating activities:		
Expenses on new options/bonds	85	94
Depreciation	356	361
Losses on sales of property, plant, & equipment	-2	0
Changes in:		
Inventories	-432	423
Other assets	664	80
Trade accounts payable	-488	-483
Accruals	-655	-672
Other liabilities and deferred income	-2,176	3,145
Net cash used by operating activities	-3,596	599
Cash flow from investing activities		
Purchases of property, plant, & equipment	-126	-53
Sales of property, plant, & equipment	2	0
Net cash from investing activities	-124	-53
Cash from financing activities		
Net proceeds from capital increase	0	14,409
Proceeds from stock options	77	68
Repayments of/proceeds from loans	13	1,600
Principal payments under finance lease obligations	-76	-79
Net cash from financing activities	14	15,998
Currency translation	-17	-5
Increase/decrease in cash and cash equivalents	-3,723	16,539
Cash and cash equivalents at beginning of period	48,460	21,444
Cash and cash equivalents at end of period	44,737	37,983

Supplementary schedule of non-cash financing activities:

Like in the reference period last year, no new leasing obligations for new laboratory and office equipment were incurred during the first quarter 2005.

Cash expenditure for interest in the first quarter 2005 was 39 T€, and 7 T€ in last year's reporting period.

Selected Details on the Notes

These unaudited consolidated financial statements were prepared in compliance with the International Financial Reporting Standards (IFRS) for the first time. It is the Management Board's conviction that the quarterly financial statements on hand reflect all adjustments required for the presentation of the assets, financial and income situation at the end of the periods that expired in March 2004, and 2005.

The quarterly financial statements on hand should be read in connection with the annual financial statements for 2003 and 2004.

Except for the adjustments outlined below, the first-time adoption of IFRS does not lead to any major adjustments when compared to the consolidated financial statements under US GAAP as of December 31, 2004.

A) Accounting and Valuation Principles

Since January 1, 2005, International Financial Reporting Standards are mandatory, in compliance with EU ordinance. The basic rule of IFRS 1 requires the complete retrospective implementation of all standards and interpretations applicable as of closing date of the first financial statements according to IFRS.

First-time adoption of the International Financial Reporting Standards (IFRS)

The consolidated financial statements of MediGene will be prepared according to IFRS at the reporting date December 31, 2005, for the first time. The transition from US GAAP to IFRS was conducted according to IFRS 1, First-time Adoption of International Financial Reporting Standards. Therefore, MediGene fully applies the standards mandatory as of December 31, 2005, in the quarterly financial statements on hand.

The consolidated financial statements were prepared according to US GAAP at the reporting date December 31, 2004, for the last time. Differences in accounting, valuation and consolidation methods between US GAAP and IFRS were adjusted according to IFRS. This applies to both reporting and comparing periods.

Adjustments and explanations required by IFRS 1 accounting for the changes in shareholders' equity and the consolidated financial statements are presented in note C - G.

As of the transition date January 1, 2004 MediGene chose the following IFRS 1 optional exemptions:

Business combinations

In 2001, MediGene acquired a company. The management decided to make use of the optional exemption of IFRS 1 concerning business combinations. Therefore previous accounting for business combinations prior to the transition date (January 1, 2004) will not be adjusted.

Foreign currency translation differences

IFRS 1 allows the prospective application of IAS 21 ("The Effects of Changes In Foreign Exchange Rates"). Hence, all currency gains and losses accrued under US GAAP prior to the transition date will be reclassified. Differences from currency translations after the transition date have to be recognized separately for each subsidiary abroad.

Compound financial instruments

The sub-division of compound financial instruments into an equity and and a debt component was made only insofar as the debt component was still in existence at the transition date (January 1, 2004). These financial

instruments will be reported according to IAS 32, and IAS 39, respectively: The equity element is calculated as the difference between proceeds and the fair value of future payment obligations (debt component).

Share-based compensation

Equity compensation such as stock options and convertible bonds granted to employees will be reported according to IFRS 2. Equity instrument issued prior to 2003 are not recognized, as those instruments have become non-forfeitable as of January 1, 2005. The valuation of these instruments is based on a suitable option-pricing model which takes into account, among others, blocking periods, vesting periods, hurdle rates, volatility of the underlying share price and risk-free interest rates.

Other options

According to IFRS 1, no further exemptions were applied for the transition from US GAAP to IFRS.

Mandatory exemptions

The application of mandatory exemptions of IFRS 1 did not lead to any adjustments.

The effects of the exemptions applied are described in paragraphs C –G.

B) Consolidation principles

In addition to the financial statements of MediGene AG Martinsried, group accounts include the statements of the wholly-owned subsidiary MediGene, Inc., San Diego, of LARNAX GmbH, Martinsried since March 31, 2003, and, as of August 13, 2004, MediGene Oncology GmbH, Martinsried. As per December 31, 2003, LARNAX GmbH discontinued its business operations. As per March 31, 2005, MediGene AG owned no other stakes in affiliated companies, associated companies or partnerships.

The companies included in the consolidation have applied uniform accounting and valuation methods.

All intercompany receivables and payables, revenues, expenses and income as well as interim results of the companies consolidated were eliminated during consolidation. Interim results from intracompany deliveries and services are deducted if realized by services to third parties.

C) IFRS adjustments and comments on the consolidated income statements (p. 21-22)

Share-based compensation

Equity compensation such as stock options and convertible bonds granted to employees will be reported according to IFRS 2. Equity instruments issued prior to 2003 are not recognized. The valuation of these instruments is based on a suitable option-pricing model. The valuation of options granted in 2004 is based on the following assumptions and terms of the underlying contracts: blocking period of 2 years, vesting period of 4 years, hurdle rate of 120 % referring to the underlying share price, expected volatility of 106 % and a risk-free interest rate of 5.65 %, as well as an expected dividend payment $0 \in$.

In 2004, expenses for share-based compensation amounted to a total of 360 T€, which are allocated as follows: 127 T€ from options issued in 2003, 215 T€ from options issued in 2004, and 18 T€ paid for interest of convertible bonds. For the first quarter 2004, expenses were 93 T€, of which 32 T€ allocated to options issued in 2003, 53 T€ to options issued in 2004, and 8 T€ paid for interest of convertible bonds.

Depreciation intangibles and fixed assets

Depreciation and Amortization of tangible and intangible assets will not be reported separately, but instead be allocated to expenses for Selling, General and Administration as well as to Research and Development.

D) IFRS adjustments and comments on the balance sheet (p. 24-26)

Capital reserves

As per December 31, 2003, capital reserves amounted to 218,177 T€ according to US GAAP. According to IFRS, the amount rose by 111 T€ to 218,288 T€ as per January 1, 2004.

As per December 31, 2004, capital reserves amounted to 256,411 T€ according to US GAAP. According to IFRS, the amount rose by 471 T€ to 256,882 T€.

As per March 31, 2004, capital reserves amounted to 230,609 T€ according to US GAAP. According to IFRS, the amount rose by 204 T€ to 230,813 T€.

The above differences are due to the recognition of the share-based compensation plan and interest expenses for convertible bonds.

Accumulated deficit

As per December 31, 2003, the accumulated deficit according to US GAAP amounted to 199,943 T€. According to IFRS, the deficit rose by 1,057 T€ to 201,000 T€ as per January 1, 2004, from which 975 T€ account for gains and losses from currency translations, accrued under US GAAP prior to the transition date.

As per December 31, 2004, the accumulated deficit according to US GAAP amounted to 212,248 T€. According to IFRS, the deficit rose by 1,416 T€ to 213,664 T€, from which 975 T€ account for gains and losses from currency translations, accrued under US GAAP prior to the transition date.

As per March 31, 2004, the accumulated deficit according to US GAAP amounted to 199,943 T€. According to IFRS, the deficit rose by 1,057 T€ to 201,000 T€, from which 975 T€ account for gains and losses from currency translations, accrued under US GAAP prior to the transition date.

These gains and losses will have to be recognized for subsidiaries abroad only after transition date. In addition, expenses of the share-based compensation plan and interest expenses for convertible bonds have been accounted for.

Net income recognized directly in equity

As per December 31, 2003, the net income directly recognized in equity according to US GAAP amounted to –220 T€. The presentation according to IFRS leads to a gain of 975 T€ to 755 T€.

As per December 31, 2004, the net income directly recognized in equity amounted to –1,003 T€ according to US GAAP. The presentation according to IFRS leads to a gain of 975 T€ to -28 T€.

As per March 31, 2004, the net income directly recognized in equity amounted to 206 T€ according to US GAAP. The presentation according to IFRS leads to a gain of 975 T€ to 1,180 T€.

The difference arose from the reclassification of gains and losses from currency translations of 975 T€.

E) Transition to IFRS and comments on the cash flow statement

Altogether no adjustments to the cash flow statement of the first quarter 2004 were made. The increase in the net loss of the period due to the recognition of share-based compensation of 94 T€ is compensated by the cash flow from operating activities and financing activities.

F) Comments on consolidated shareholders' equity statement

See also comments on the balance sheet (P. 19).

G) Other comments

Contingencies and other financial obligations

As of March 31, 2005, a rental guarantee of 206 T€ existed. No contingencies for the benefit of board members were assumed.

H) Board of directors and supervisory board

"Directors Holdings" and Notes on Company-Owned Shares and Warrants

Members	Shares Q1-2005	Shares Y-2004	Options Q1-2005	Options Y-2004	CB ¹⁾ Q1-2005	CB ¹⁾ Y-2004
Prof. Dr. Ernst-Ludwig Winnacker Supervisory Board Chairman, Co-						
founder	292,676	292,676	38,700	38,700	3,200	3,200
Dr. Norbert Riedel						
Deputy Chairman of the Supervisory Board	3,300	3,300	5,590	5,590	0	0
Dr. Pol Bamelis	-,	0,000	-,	0,000		
Supervisory Board Member	1,000	1,000	0	0	1,200	1,200
Dr. Alexandra Goll						
Supervisory Board Member	0	0	0	0	0	0
Dr. Manfred Scholz						
Supervisory Board Member	90,000	142,841	0	0	0	0
Michael Tarnow						
Supervisory Board Member	6,337	6,337	0	0	36,200	36,200
Total Supervisory Board	393,313	446,154	44,290	44,290	35,600	40,600
Dr. Peter Heinrich						
Chief Executive Officer, Co-founder	503,505	503,505	76,636	76,636	0	0
Dr. Ulrich Delvos						
Executive Board Member for R&D	360	360	0	0	0	0
Alexander Dexne						
Chief Financial Officer	0	0	60,000	60,000	0	0
Total Executive Board	503,865	503,865	136,636	136,636	0	0
Shareholders' equity MediGene AG	0	0	0	0	0	0

1) Convertible Bonds

(Status as at March 31, 2005, and December 31, 2004)

I) Adjustments US-GAAP to IFRS

Adjustment Consolidated Income Statements of MediGene AG for the periods from January 1 to December 31, 2004

		IFRS	IFRS
	US GAAP	-	-
in T€	2004 unaudited	adjustment	2004
		0	unaudited
1. Product sales	12,501 657	0	12,501
 Other operating income Total revenues 		0	657 13,138
	13,138		
4. Cost of sales	5,930	0	5,930
5. Gross profit	7,208	0	7,208
6. Selling expenses	1,164	0	1,164
7. General and administrative expenses	4,788	342	5,130
8. Research and development expenses	15,627	0	15,627
9. Operating loss	-14,371	-342	-14,713
 Interest income and expenditures Income from securities 	575	-18	557
	1,581	0	1,581
12. Foreign currency exchange gains/losses	-90	0	-90
13. Loss before income tax	-12,305	-360	-12,665
14. Tax	0		0
15. Net loss from continued operations	-12,305	-360	-12,665
16. Result from discontinued operations	-1		-1
17. Net loss for the period	-12,306	-360	-12,666
Per share data in €:			
Result from continued operations ("actual" and "fully diluted ")	-0.88	-0.02	-0.90
Result including discontinued operations ("actual" and "fully diluted")	-0.88	-0.02	-0.90
Weighted average number of shares outstanding	13,996,440		13,996,440

Adjustment Consolidated Income Statements of MediGene AG for the periods from January 1 to March 31, 2004

	US GAAP	IFRS	IFRS
	Q1-2004	adjustment	Q1-2004
in T€	unaudited		unaudited
1. Product sales	3,857	0	3,857
2. Other operating income	53	0	53
3. Total revenues	3,910	0	3,910
4. Cost of sales	28	0	28
5. Gross profit	3,882	0	3,882
6. Selling expenses	299	0	299
General and administrative expenses	1,014	85	1,099
Research and development expenses	3,795	0	3,795
9. Operating loss	-1,226	-85	-1,311
10. Interest income and expenditures	99	-8	91
11. Foreign currency exchange gains/losses	-2	0	-2
12. Loss before income tax	-1,129	-93	-1,222
13. Tax	0		0
14. Net loss from continued operations	-1,129	-93	-1,222
15. Result from discontinued operations	-281		-281
16. Net loss for the period	-1,411	-93	-1,503
Per share data in €:			
Result from continued operations ("actual" and "fully diluted ")	-0.09	-0.01	-0.10
Result including discontinued operations ("actual" and "fully diluted")	-0.11	-0.01	-0.12
Weighted average number of shares outstanding	12,340,119		12,340,119

Adjustment Consolidated Balance Sheet of MediGene AG as of January 1, 2004

	US-GAAP	IFRS	IFRS
in T€	December 31,	Adjustment	January 1,
	2003		2004
	audited		unaudited
Assets			
A. Long-term assets			
I. Property, plant & equipment	2,189	0	2,189
II. Intangible assets	76	0	76
III. Goodwill	9,226	0	9,226
IV. Investments	4,452	0	4,452
V. Other assets	42	0	42
Total long-term assets	15,985	0	15,985
B. Current assets			
I. Inventories	0	0	0
II. Accounts receivable	79	0	79
III. Cash & cash equivalents	21,444	0	21,444
IV. Other current assets	859	0	859
Total current assets	22,382	0	22,382
	,•••_		,
Total assets	38,367	0	38,367
Liabilities and shareholders' equity in T€			
A. Shareholders' equity			
I. Share capital	11,206	0	11,206
Number of shares issued and outstanding:	,	-	,
December 31, 2003: 11,206,205			
II. Additional paid-in capital	218,177	111	218,288
III. Accumulated deficit	-199,943	1,057	-201,000
IV. Net income recognized directly in equity	-220	975	755
Total shareholders' equity	29,220	29	29,249
B. Long-term liabilities			
I. Long-term debt less current portion	108	-29	79
II. Other long-term liabilities	34	0	34
III. Capital lease obligation less current portion	108	0	108
IV. Pension accrual	35	0	35
Total long-term liabilities	285	-29	256
C. Current lipbilities			
C. Current liabilities	1 764	0	4 764
 I. Trade accounts payable II. Other current liabilities 	1,764	0	1,764
	3,222	0	3,222
III. Current portion of capital lease obligation	268	0	268
IV. Accruals V. Deferred income	265	0	265
Total current liabilities	3,342	0	3,342
	8,862	0	8,862

Adjustment Consolidated Balance Sheet of MediGene AG as of January 1, 2004

in T€	US-GAAP December 31,	IFRS Adjustment	IFRS December 31,
in re	2004	Aujustinent	2004
	audited		unaudited
	addited		undulied
Assets			
A. Long-term assets			
I. Property, plant & equipment	1,565	0	1,565
II. Intangible assets	7,020	0	7,020
III. Goodwill	9,226	0	9,226
IV. Investments	2,761	0	2,761
V. Other assets	133	0	133
Total long-term assets	20,705	0	20,705
B. Current assets			
I. Inventories	0	0	0
II. Accounts receivable	115	0	115
III. Cash & cash equivalents	48,460	0	48,460
IV. Other current assets	3,614	0	3,614
Total current assets	52,189	0	52,189
	02,100		02,100
Total assets	72,894	0	72,894
Liabilities and shareholders' equity in T€			
A. Shareholders' equity			
I. Share capital	18,523	0	18,523
Number of shares issued and outstanding:	10,525	0	10,020
December 31, 2004: 18,522,684			
II. Additional paid-in capital	256,411	471	256,882
III. Accumulated deficit	-212,248	-1,416	-213,664
			-213,004
IV. Net income recognized directly in equity Total shareholders' equity	-1,003 61,683	975 29	-20 61,712
Total shareholders equity	01,000	۲ ۷	01,712
B. Long-term liabilities			
I. Long-term debt less current portion	1,703	-29	1,674
II. Other long-term liabilities	55	0	55
III. Capital lease obligation less current portion	115	0	115
IV. Pension accrual	36	0	36
Total long-term liabilities	1,909	-29	1,880
C. Current liabilities			
I. Trade accounts payable	618	0	618
II. Other current liabilities	3,463	0	3,463
III. Current portion of capital lease obligation	269	0	269
IV. Accruals	2,953	0	2,953
V. Deferred income	2,000	0	2,000
Total current liabilities	9,303	Õ	9,303
	70.004	~	70.004
Total liabilities and shareholders' equity	72,894	0	72,894

Adjustment Consolidated Balance Sheet of MediGene AG as of March 31, 2004

in T€	US-GAAP March 31, 2004 audited	IFRS Adjustment	IFRS March 31, 2004 unaudited
Assets			
A. Long-term assets			
I. Property, plant & equipment	1,894	0	1,894
II. Intangible assets	70	0 0	70
III. Goodwill	9,226	0 0	9,226
IV. Investments	4,877	0	4,877
V. Other assets	42	0	42
Total long-term assets	16,109	0	16,109
B. Current assets			
I. Inventories	423	0	423
II. Accounts receivable	0	0	0
III. Cash & cash equivalents	37,983	0	37,983
IV. Other current assets	858	0	858
Total current assets	39,264	0	39,264
Total assets	55,373	0	55,373
Liabilities and shareholders' equity in T€ A. Shareholders' equity			
I. Share capital Number of shares issued and outstanding: March 31, 2004: 13,474,032	13,474	0	13,474
II. Additional paid-in capital	230,609	204	230,813
III. Accumulated deficit	-201,352	-1.150	-202,502
IV. Net income recognized directly in equity	205	975	1,180
Total shareholders' equity	42,936	29	42,965
B. Long-term liabilities			
I. Long-term debt less current portion	1,428	-29	1,399
II. Other long-term liabilities	34	0	34
III. Capital lease obligation less current portion	71	0	71
IV. Pension accrual	35	0	35
Total long-term liabilities	1,568	-29	1,539
C. Current liabilities			
I. Trade accounts payable	1,281	0	1,281
II. Current portion of long-term debt	3,282	0	3,282
III. Other current liabilities	271	0	271
IV. Current portion of capital lease obligation	222	0	222
V. Accruals	2,670	0	2,670
VI. Deferred income	3,143	0	3,143
Total current liabilities	10,869	0	10,869
Total liabilities and shareholders' equity	55,373	0	55,373

Financial Calendar / Imprint

2005

May 4 3-Months Report Press and analysts conference call

June 10 Annual shareholders' meeting, Munich

August 3 6-Months Report Press and analysts conference call

November 2 9-Months Report Press and analysts conference call

2006

March 22 Annual Report 2005 Press and analysts conference

Publisher

MediGene AG Lochhamer Straße 11 82152 Planegg / Martinsried T +49 (89) 85 65 29 0 F +49 (89) 85 65 29-20

Contact

Investor Relations

Dr. Michael Nettersheim T +49 (89) 85 65 29-46 investor@medigene.com

Public Relations

Julia Hofmann T +49 (89) 85 65 29-86 public.relations@medigene.com

Human Resources

Dr. Annette Erdmann T +49 (89) 85 65 29-49 human.resources@medigene.com

Business Development

Dr. Michael Ruppert T +49 (89) 85 65 29-56 business.development@medigene.com

...we look forward to speaking with you